Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
Nadda also commended the role of ASHA workers, “grassroot foot soldiers”, in the healthcare system
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
Subscribe To Our Newsletter & Stay Updated
